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Background: K-ras mutations are a key step in colorectal cancer progression. Such mutations have been widely
studied in case series from Western countries but there are few data on the rate and spectrum of mutations in tumors
from countries where the epidemiological features of the disease are different.
Patients and methods: Tumor samples from 182 Iranian colorectal cancer patients (170 sporadic cases and
12 HNPCC cases) were screened for K-ras mutations at codons 12, 13 and 61 by sequencing analysis. The
cases were also characterized for microsatellite instability at mononucleotide repeats by PCR and fragment analysis,
and classified according to microsatellite instability status. The frequency and the spectrum of K-ras mutations were
compared with those observed in a series of colorectal cancer patients from Italy.
Results: K-ras mutations were observed in 68/182 (37.4%) cases. Mutation frequencies were similar in HNPCC-
associated, sporadic MSI-H and sporadic microsatellite-stable (MSS) tumors. However, the G13D substitution was
more frequent in HNPCC (3/4, 75%) and sporadic MSI-H (7/11, 63.6%) tumors compared to sporadic MSS tumors
(11/53, 20.4%) (P <0.01). Comparison of mutations in the two series from Iran and Italy showed a significantly higher
frequency of G13D among Italian patients.
Conclusions: While the frequency of K-ras mutations could be similar, the mutational spectrum could be
differentially influenced by genetic and environmental factors.
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introduction
Cancer development and progression is a multi-step process
based on the accumulation and clonal selection of somatic
mutations in key cancer-related genes [1]. Colorectal carcinoma
(CRC) provides a classic model for the study of such mutations
[2]. Several epidemiological studies strongly suggest that the
differences in CRC incidence observed among world
populations could be at least partly attributable to differences in
environmental factors, with particular regard to dietary
components [3, 4]. Thus studying and comparing the molecular
characteristics of CRCs from populations differing in ethnicity
and environmental exposures could advance our understanding
of the gene-environment interactions that influence colorectal
carcinogenesis.
Mutations activating the K-ras proto-oncogene are
considered a key step in the progression from normal colorectal
epithelium to carcinoma [2]. K-ras is activated by point
mutations resulting in single amino acid substitutions.
Mutations in codons 12, 13 and 61 have been found in
approximately 25%–50% of all CRCs [5–7]. Different dietary
carcinogens have been shown to induce characteristic K-ras
point mutations [8, 9].
High-level microsatellite instability (MSI-H) is a form of
genomic instability that occurs in hereditary non-polyposis
colorectal cancer (HNPCC) and in about one-fifth of all
sporadic CRCs [10]. MSI-H is attributed to defects in DNA
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mismatch repair (MMR). Although genes with repetitive
sequences are clear targets of defective MMR, mutations in non-
repetitive sequences are also found in MSI-H tumors. MSI-H
CRCs, whether inherited or sporadic, tend to be right-sided and
to show poorly differentiated mucinous phenotype. It has been
a matter of controversy whether CRCs with deficient versus
competent MMR share the same pattern of somatic alterations
in K-ras.
A number of studies analyzed the rate and spectrum of K-ras
mutations in relation to MSI status. Most authors reported
similar frequencies of K-ras mutations in HNPCC-related and
sporadic CRCs [11–14] as well as in MSI-H and microsatellite-
stable (MSS) CRCs, although this was not confirmed in other
studies [15, 16]. Overall the vast majority of the studies were
based on patients from Western countries, and there are few
data available on the mutational characteristics of tumors from
developing countries. The incidence rates of colorectal cancer in
developing countries have been shown to be lower compared
with the figures observed in the West. However a marked
increase in CRC incidence has been observed during the last
decades in various countries, including Iran [17–19]. A possible
explanation for the reported CRC increase in Iran might be
related to changes in dietary habits and lifestyle.
We have analyzed K-ras mutation rate and spectrum in
a hospital-based Iranian CRC series presenting a relatively high
frequency of clinically-diagnosed HNPCC [20]. The spectrum
of K-ras mutations detected in this case series has been
correlated with the presence or absence of clinical HNPCC
criteria and with tumor MSI status. Furthermore, the frequency
and pattern of K-ras mutations found in the Iranian series have
been compared with those observed in a well-characterized CRC
series from southern Italy [21].
patients and methods
cases and DNA extraction
One hundred and ninety formalin-fixed, paraffin-embedded CRC cases
from patients who underwent surgical resection from February 1998 to
September 2003 in two major hospitals in Tehran (Atieh and Mehr) were
selected for this study. Patients with CRC associated with inflammatory
bowel disease, familial adenomatous polyposis and patients who had
undergone preoperative chemotherapy or radiotherapy were not included.
Out of 182 patients whose samples could be successfully analyzed, 79
(43.4%) were females and 103 (56.6%)males. Fifty-eight (32%) tumors were
located in the right side of the colon, 65 (35.7%) in the left colon and 53
(29%) in the rectum, the location of six (3.3%) tumors was not specified.
The study was reviewed and approved by the ethics committee of the
Digestive Disease Research Center of Tehran University of Medical Sciences.
Archived histological sections were reviewed by the collaborating
pathologists in Tehran. Colorectal adenocarcinoma diagnosis was confirmed
after review at the Pathology Section of the Center of Excellence on Ageing
(CeSI), Chieti, Italy.
For each case an area with at least 50% neoplastic cells and an area
including normal muscularis propria and/or CRC-unaffected mucosa was
identified on H&E-stained slides and used to guide manual microdissection
for DNA extraction. Serial sections of 15-lm thickness were prepared for
DNA extraction. Selected areas were dissected from de-waxed step-sections
by gentle scraping. Scraped tissue was digested by incubation for 1–2 days at
56C in 100 ll of buffer containing TRIS (50 mM pH 8,5), EDTA (1 mM),
TWEEN 20 (0,5%) and proteinase K (20 mg/ml). The extracted DNA was
purified with the QIAamp DNA minikit (Qiagen, Hilden, Germany)
following manufacturer’s instructions.
K-ras analysis
De-waxing, microdissection, DNA extraction and PCR set-up were all
performed in a dedicated laboratory free of contamination from PCR
products. Exons 1 and 2 of K-ras were individually amplified by 40-cycle
PCRs using primers specific for the K-ras gene. Primers for exon 1 were:
K-ras -F: 59-TTTTATTATAAGGCCTGCT-39 and K-ras -R: 59-
GTCCTGCACCAGTAATATGC-39. PCRs were in 30 ll volumes with
10 mM Tris (pH 8.3), 1.5 mM MgCl2, 200 lM dNTPs, 1.5 units of
AmpliTaq Gold (Applied Biosystems, Foster City, CA), 0.5 lM of each
primer and 1–3 ll of DNA extract. PCR conditions were 40 cycles of
50C for 45 s, 72C for 45 s and 94C for 30 s using a GeneAmp PCR System
9700 (Applied Biosystems, Foster City, CA). Primers and PCR condition
for exon 2 were as described by Semczuk et al. [22]. PCR products were
visualized by ethidium bromide staining on 2% agarose gel electrophoresis
and purified with Montage PCR microfilters (Millipore Corporation,
Bedford, MA). PCR products were directly sequenced using the ABI PRISM
Big Dye Terminator v3.1 Cycle Sequencing Ready Reaction Kit and
visualized by capillary electrophoresis with an ABI 310 Genetic Analyzer
according to the supplier’s instructions (Applied Biosystems, Foster City,
CA, USA). All samples with mutations were verified by two independent
cycle sequencing PCR reactions and analysis of both DNA strands.
MSI analysis
DNA frommicrodissected normal and tumor areas was purified as described
above. MSI analysis was based on two mononucleotide repeats, BAT25 and
BAT26, known to be the most sensitive markers of MSI-H status and widely
regarded as sufficient for the identification of CRCs with MMR defect [23,
24]. PCRs for repeats were performed using 6-FAM-labelled forward
primers. The sequences of the oligonucleotides were as follows: BAT25-F: 59-
CTAAAGAGTTTTGTGTTTTG-39and BAT25-R: 59-
GGCTCTAAAATGCTCTG-39; BAT26-F: 59-
TACTTTTGACTTCAGCCAG-39 and BAT26-R: 59-
CCAATCAACATTTTTAACCC-39. PCR for both markers were carried
out in 20 ll volumes containing PCR buffer, 1.5 mM MgCl2, 0.4 lM of
primers, 0.2 mM each dNTP and 0.5 units AmpliTaq Gold. PCRs
consisted of an initial denaturation step at 94C for 10 min, followed by
35 cycles at 94C for 10 s, 55C for 30 s and 72C for 2 min, and a final
extension step at 72C for 10 min. An aliquot (1.5 ll) of the product was
mixed with 0.05 ll of ROX size standard, 9 ll formamide and 0.45 of
ddH2O. The samples were then denatured and loaded onto an ABI Prism
3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). The
data were processed using GeneScan software. A difference in the
electrophoretogram pattern between normal and tumor DNA was
regarded as evidence of MSI for that marker. The tumors were classified
as MSI-H when at least one of the two markers showed tumor-associated
allele shifts.
comparisons of K-ras mutation frequencies
Patients belonging to families fulfilling the Amsterdam II criteria (i.e. at least
three members with an HNPCC-associated cancer—colorectal, endometrial,
small bowel, ureter, renal pelvis—in at least two successive generations, one
being a first-degree relative of the other two and at least one diagnosed
before the age of 50 years), were classified as HNPCC [25]. The remaining
CRC cases were classified according to MSI status in MSS and MSI-H. The
spectra of K-ras mutations (codon distribution and type of mutation) were
compared in these subgroups.
The overall observed frequency and spectrum of K-ras mutations were
also compared with the relevant data from 160 CRC patients from southern
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Italy previously described by Bazan et al. [21]. Statistical comparisons
were performed by v2 and Fisher’s exact tests using SPSS for IBM PC
(Chicago, IL). P values <0.05 were considered significant.
results
Of the 182 Iranian CRCs analyzed in this study 68 (37.4%)
showed K-ras mutations. The frequency of K-ras gene
mutations observed in women (34/79, 43%) was slightly higher
than that observed in men (34/103, 33%), but the difference was
not significant (P = 0.12).
Of all CRCs, 12 cases were classified as HNPCC according to
Amsterdam II criteria. MSI analysis was done in all 182 tumors;
all HNPCC cases were MSI-H, of the remaining 170 sporadic
cases 33 (19.4%) were MSI-H and 137 (80.6%) did not
show microsatellite instability at the markers tested and were
classified as MSS.
In the 68 samples with K-ras mutations, codon 12 was the
most frequently mutated (45/68 cases, 66%), followed by codon
13 (22/68 cases, 32.5%), while codon 61 was the least mutated
(1/68 cases, 1.5%). K-ras mutations were then compared in the
three CRC subgroups (MSI-H HNPCC-associated, 12 cases;
sporadic MSI-H, 33 cases; sporadic MSS, 137 cases). The overall
prevalence of K-ras mutations was not different between these
groups [HNPCC-associated: 4/12 (33.3%), sporadic MSI-H: 11/
33 (33.3%) and sporadic MSS: 53/137 (38.7%), Table 1].
However the frequencies of K-ras mutations at codons 12 and
13 differed according to MSI status (Table 1). Sporadic MSS
CRCs harbored a significantly lower frequency of mutations
at codon 13 compared with sporadic MSI-H or HNPCC-
associated CRCs (23% versus 63.5% and 75% respectively;
Table 1).
K-rasmutation types also tended to differ in these subgroups.
G to A transitions and G to T transversions were observed with
similar frequencies (47% and 49%, respectively) in sporadic
CRCs with MSS phenotype. However, G to A transitions were
the most frequent mutation in HNPCC-associated CRCs
(100%, 4/4 with K-ras mutation) and in MSI-H CRCs (82%,
9/11 with K-ras mutation; Table 1).
The type of K-ras amino acid change also varied among the
three CRC subgroups. The frequency of glycine to aspartate
(G13D) substitutions at codon 13 was significantly higher in
HNPCC-associated and sporadic MSI-H cases compared with
sporadic MSS cases (Table 1). There was also a trend (P = 0.099)
towards a higher frequency of G12V, resulting from a G to T
substitution, in sporadic MSS cases compared with the other
two subgroups (Table 1).
The frequency and spectrum of K-ras mutations found in the
Iranian case series were then compared with those observed in
the CRC patients from southern Italy (Table 2). In the Italian
series the frequency of K-ras mutations (74/160, 46.3%) was
higher than that observed in the Iranian CRCs (68/182, 37.4%),
but the difference did not reach statistical significance (P =
0.09). We also compared the spectrum and codon distribution
of the K-ras mutations detected in the two series. G to A
transitions were more frequent in the series from Italy (Table 2).
Codon 13 was more frequently affected in the Italian CRCs,
whereas codon 12 was equally affected in both series (Table 2).
Comparison of the two series with regard to K-ras amino
acid change showed that G13D was significantly more frequent
in the Italian CRCs. Other K-ras amino acid changes did not
differ between the two series (Table 2).
discussion
It is widely accepted that mutations that activate K-ras are
among the critical transforming genetic alterations occurring
during human colorectal tumorigenesis [2]. Although K-ras
mutations have been widely studied in CRCs from Western
countries there are few data on K-ras mutation rate and
spectrum in CRCs from developing countries, such as Iran. Iran
has an age-adjusted CRC incidence rate of 6–7.9 per 100 000
persons/year [17, 26], which is remarkably lower than the rates
reported in Western countries, ranging from 20 to 40 per
Table 1. Frequency of K-ras mutations, nucleotide substitutions and amino acid changes in three clinical settings of 182 colorectal cancers
HNPCC
(n = 12)
MSI-H
(n = 33)
MSS
(n = 137)
P value
K-ras mutation
Present 4 (33.3%) 11 (33.3%) 53 (38.7%) 0.8
Mutated codona
Codon 12 1 (25%) 4 (36.5%) 40 (77%) <0.01
Codon 13 3 (75%) 7 (63.5%) 12 (23%)
Total nucleotide substitutionsb
G/ A 4 (100%) 9 (82%) 25 (47%) <0.01
G/ T 0 (0) 2 (18%) 26 (49%)
Amino acid changesc
G12D transition at 2nd pos. codon 12 (Asp) 1 (25%) 2 (18.2%) 13 (24.1%) 0.9
G12C transversion at 1st pos. codon 12 (Cys) 0 (0) 1 (9.1%) 8 (14.8%) 0.6
G12V transversion at 2nd pos. codon 12 (Val) 0 (0) 1 (9.1%) 17 (31.5%) 0.1
G13D Transition at 2nd pos. codon 13 (Asp) 3 (75%) 7 (63.6%) 11 (20.4%) <0.01
aCodon 61 was only mutated in one tumor and was not considered for statistical analysis.
bA/ C (codon 61) and G/ C each were observed in only one tumor and were not considered for statistical analysis.
cG12S, G12A, G13C and Q61H were each observed in one tumor and were not considered for statistical analysis.
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100 000 persons/year [27]. Nevertheless, the frequency of
familial forms of CRC such as HNPCC seems to be relatively
high in Iran (4.7%) [20]. This is consistent with the results of
our study showing a relatively high percentage of MSI-H CRCs
meeting HNPCC criteria in the presently analyzed series.
Overall, we found 45/182 (24.5%) patients with MSI-H
phenotype (including HNPCC patients), a rate higher than
reported in studies from Western countries (12%–17%) [10,
28]. This may also be related to the relatively high number of
right-sided CRCs in the series (58/182, 32%), which is
consistent with results from a population-based study in Iran
indicating a relatively high rate of proximal colon cancer [17].
In this study, conducted on 182 Iranian CRCs from Tehran,
we found an overall K-ras mutation rate of 37.4%. This rate is
within the range of 25%–50% reported in studies of other CRC
series [5–7]. The frequency of K-ras mutations did not differ
between HNPCC-associated, sporadic MSS and sporadic MSI-
H CRCs. In line with this observation there is some evidence
[11–14] that HNPCC-associated CRC may progress through
molecular pathways similar to those of sporadic CRC with
regard to K-ras mutations. It has also been reported that the
subset of sporadic MSI-H CRC with hypermethylation of the
hMLH1 promoter is less frequently mutated in K-ras compared
with sporadic MSI-H CRC negative for hMLH1 methylation
and to both HNPCC-associated and MSS CRC [14].
Mutations of K-ras result in specific amino acid substitutions
that lead to permanent activation of the encoded p21 ras protein
[29]. It is well known that activating K-ras mutations cluster at
codons 12 and 13 (GTP-binding domain). In the current Iranian
series, 98.5% of the detected mutations occurred at these codons
and only one CRC carried a mutation at codon 61. This confirms
that codons 12 and 13 are preferentially involved in CRC
progression also in the Iranian population. Looking at codons 12
and 13, we found significant differences between HNPCC-
associated, sporadic MSI-H and sporadic MSS CRC. The
frequency of K-rasmutations at codon 12 was higher in sporadic
MSS cases whereas mutations at codon 13 were much more
common in HNPCC-associated and sporadic MSI-H CRCs.
The type of K-ras mutation also differed between CRC
subgroups. The frequency of G to A transitions was significantly
higher in HNPCC-associated and sporadic MSI-H CRC than in
MSS CRC. Thus hereditary and sporadic tumors with MSI-H
seemed to preferably harbor G to A transitions, suggesting a link
between this specific type of mutation and MMR defect. In this
respect it could be noteworthy that defects in other DNA repair
systems, such as O6-methylguanine-DNA methyltransferase
(MGMT) activity, are linked to inability to protect from G to A
transition in K-ras induced by alkylating agents [30–32]. It has
been suggested that other repair systems could also contribute to
this repair mechanism [31]. Further grouping of K-ras
mutations with regard to type and nucleotide position showed
that G13D, resulting from a G to A transition at the second
nucleotide of codon 13, was significantly less frequent in
sporadic MSS CRC while it had the highest frequency in
HNPCC-associated CRC. This is in concordance with other
reports, which showed that G13D is the most common type of
K-ras mutation in HNPCC-associated CRC [13, 14]. In
addition, consistently with other studies [14, 33] the frequency
of G12V was considerably high (31.5%) in sporadic MSS CRCs
(Table 1).
Apart from genetic factors, accumulating evidence suggests
that environmental factors such as diet could be involved in
CRC progression and could induce specific K-ras mutations.
Diet-related carcinogens can induce K-ras mutations [34] and
dietary components were shown to influence the rate and
spectrum of K-ras mutations in CRC [8]. Dietary factors may
also affect clonal selection by modifying the growth of tumors
harboring specific K-ras mutations [35, 36]. This could link
specific types of K-ras mutations with specific nutritional
patterns, deficient or excessive in particular dietary
component(s).
We compared the rate and spectrum of CRC-associated K-ras
mutations from Iran and Italy as representatives of countries
with differences in CRC incidence [26, 27]. We found an overall
rate of K-ras mutations of 37.4% in the Iranian CRC series and
of 46% in the Italian series. Although there is a considerable
Table 2. Frequency of K-ras mutations, types of nucleotide substitution and amino acid changes in 182 CRCs from Iran and 160 CRCs from Italy
Iran
(n = 182)
Italy
(n = 160)
P value
Cases with K-ras mutation 68 (37.4%) 74a (46.3%) 0.09
Mutated codon
Codon 12 45 (24.7%) 46 (28.8%) 0.5
Codon 13 22 (12.1%) 34 (21.3%) <0.05
Total nucleotide substitutions
G/ A 38 (21%) 51 (32%) <0.05
G/ T 28 (15.4%) 21 (13%) 0.6
G/ C 1 (0.5%) 2 (1.3%) 0.6
Amino acid changesb
G12D transition at 2nd pos. codon 12 (Asp) 16 (8.8%) 17 (10.6%) 0.6
G12C transversion at 1st pos. codon 12 (Cys) 9 (4.9%) 9 (5.6%) 0.8
G12V transversion at 2nd pos. codon 12 (Val) 18 (9.9%) 13 (8.1%) 0.6
G13D transition at 2nd pos. codon 13 (Asp) 21 (11.5%) 32 (20%) <0.05
aIn CRCs from Italy 80 K-ras mutations were observed in 74 patients.
bG12S, G12A, G13C and Q61H were not considered for statistical analysis due to very low frequency in both series.
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difference between these two rates, this did not reach statically
significance. Moreover, G to A transitions were the most
common mutation type observed both in Iranian (57.6%) and
in Italian (70.8%) CRCs, a finding in agreement with reports
concerning other populations [5, 7]. There was a higher
frequency of G to A transitions in CRC from Italy compared to
Iran. Although mutations in codon 12 were similar in both
series, codon 13 was more frequently affected in CRC from Italy.
Comparison of the specific types of K-ras mutation between
the two series revealed that there was a significantly higher
frequency of G to A transition mutations in the second base
of codon 13 (G13D) among Italian CRCs, which mainly
contributed to the higher G to A transition rate and higher
codon 13 mutation frequency. This type of mutation has been
linked with high consumption of refined grain [8], a dietary
pattern directly associated with CRC risk [37, 38].
The Italian diet, particularly in southern Italy, is characterized
by a high intake of refined grain such as pasta and white bread as
the top two sources of energy [39, 40]. In contrast, the Iranian
diet is wheat-based with a variety of unrefined, unleavened,
whole-wheat breads comprising the main staple. Wholegrain
foods may reduce the risk of several types of neoplasms,
particularly of the digestive tract, including CRC [41].
In conclusion, in the currently studied Iranian series HNPCC-
associated CRCs, sporadic MSI-H and sporadic MSS shared
similar K-ras mutation frequencies; however, the spectrum of
K-ras mutations differed in the above mentioned CRC subsets.
Specifically, G13D mutations in K-ras seemed to be associated
with CRC characterized by defect in MMR, as indicated by MSI-H
phenotype. Furthermore, we found differences in the amino acid
changes in the series from Iran compared with that from Italy.
These could be attributed to differences in dietary habits. Overall
our data suggest that the spectrum of K-ras mutations could be
differentially influenced by genetic and environmental factors.
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